Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon

Leuk Lymphoma. 2015 May;56(5):1510-3. doi: 10.3109/10428194.2014.982644. Epub 2015 Mar 3.

Affiliation

¹ Scientific Direction, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata , Rionero in Vulture , Italy.

PMID: 25651428
DOI: 10.3109/10428194.2014.982644

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / therapeutic use*
Female
Humans
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Multiple Myeloma / pathology*
Neoplasm Staging
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Bendamustine Hydrochloride